NASDAQ:ACON Aclarion Q2 2024 Earnings Report $3.57 +0.04 (+1.13%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.42 -0.16 (-4.34%) As of 06/5/2026 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aclarion EPS ResultsActual EPS-$1,356.75Consensus EPS -$1,718.55Beat/MissBeat by +$361.80One Year Ago EPSN/AAclarion Revenue ResultsActual Revenue$0.01 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAclarion Announcement DetailsQuarterQ2 2024Date8/14/2024TimeDuring Market HoursConference Call DateTuesday, August 13, 2024Conference Call Time6:00PM ETUpcoming EarningsAclarion's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Aclarion Earnings HeadlinesWall Street Zen Downgrades Aclarion (NASDAQ:ACON) to SellJune 6 at 1:26 AM | americanbankingnews.comAclarion Stockholders Approve Directors and Equity Plan AmendmentJune 4 at 7:10 PM | tipranks.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.June 6 at 1:00 AM | Weiss Ratings (Ad)Aclarion Expands Nociscan Availability in Greater Los Angeles Through Partnership with Institute of Neuro InnovationJune 3 at 6:31 AM | quiverquant.comQAclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationJune 3 at 6:00 AM | globenewswire.comAclarion's Nociscan Technology Linked to Immune Signatures in Back Pain Study, Expanding Clinical ApplicationsJune 1, 2026 | quiverquant.comQSee More Aclarion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email. Email Address About AclarionAclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.View Aclarion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?IREN's 800MW Bet Flips the AI Power SwitchBuy the Dip? Broadcom's AI Moat Is Wider Than EverCrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?The Market Has Ollie’s Bargain Outlet Completely Wrong Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.